CLINICAL WORKSHOP IMAGE-GUIDED HDR BRACHYTHERAPY OF PROSTATE CANCER
|
|
|
- Stephen Jacobs
- 6 years ago
- Views:
Transcription
1 CLINICAL WORKSHOP IMAGE-GUIDED HDR BRACHYTHERAPY OF PROSTATE CANCER Klinikum Offenbach Nucletron April 27 th 28 th, 2014
2 History HDR Protocols for Boost and Monotherapy, Results, Logistics and Practical Issues
3 GEC / ESTRO recommendations on temporary brachytherapy for localised prostate cancer
4 GEC / ESTRO recommendations Advantage of temporary afterloading brachytherapy: accurate postitioning of the source by first implanting non-active guide needles possibility to choose the source postitions over the lenght of needle no target movement during radiation
5 GEC / ESTRO recommendations Contraindications - regional and/or distant metastatic disease - interval to TURP < 6 month - large prostatic volume defect after a previous TURP - general contraindications - anatomical abnormalities
6 Patient selection - clinical stage T1-T3b (TRUS, DRE, MRI) - N0 M0 (CT, MRI, Bone scan) - no severe co-morbidity - no pubic arch interference - Uroflow > 15 ml/s - Prostate volume < 70 ccm
7 GEC / ESTRO recommendations
8 GEC / ESTRO recommendations 6 to 12 core biopsy
9 GEC / / ESTRO recommendations recommandations The clinical team: radiotherapist medical physicist urologist
10 HDR Brachytherapy in Offenbach HDR - MONOTHERAPY HDR BOOST to EBRT HDR - SALVAGE
11 HDR-Brachytherapy of Prostate Cancer - History -
12 History 1. Prostate Brachytherapy in 1996 BOOST + EBRT
13 History from 2001: Prostate Brachytherapy MONOTHERAPY
14 History from 2002: Prostate Brachytherapy BOOST + EBRT
15 History transrectal transperineal Mono transperineal Kombi > 2500 Patients since 1996
16 HDR-Brachytherapy in Offenbach HDR boost to EBRT
17 History BOOST to EBRT Clinical stage T2c or PSA > 10.0 or Gleason 7b (4+3)
18 BOOST to EBRT Since 1996: transrectal HDR 4 X 5-7 Gy + EBRT 39,6 45 Gy 1450 Patients transperineal HDR 3 x 7,0 Gy + EBRT 45 Gy 258 Patients HDR 2 x 10,5 Gy + EBRT 45 Gy 88 Patients
19 BOOST to EBRT Protocols: 1 fraction / implant: Dinges: 2 implants (9 Gy per implant) + 45 Gy EBRT Martinez: 2 implants (11.5 Gy per implant) + 46 Gy EBRT Galalae: 2 implants (15 Gy per implant) + 50 Gy EBRT Offenbach: 2 implants (10,5 Gy per implant) + 45 Gy EBRT multiple fractions / implant Rodriguez: Pellizzon: Linares: 2 implants (2 x 6 Gy per implant) + 36 Gy EBRT 2 implants (2 x 6 Gy per implant) + 45 Gy EBRT 1 implant (4 x 5.5 Gy per implant) + 45 Gy EBRT
20 Athens History - Conference HDR BOOST + EBRT 46 Gy at 2 Gy * Dose Gy # Fxs Total D Gy BED α/β 1.5 % Dose D 2Gy *45 Gy at 1.8 Gy
21 History GEC / ESTRO recommandations Different target and treatment philosophies: CTV 1 prostate capsule CTV 2 peripheral zone CTV 3 visible tumor
22 History GEC / ESTRO recommandations EBRT BTfx Gy/fx Target Borghede et. al Tumor volume CTV3 Dinges et. al Prostate capsule CTV1 Kovács et. al. 40/ Peripheral zone CTV2 Mate et. al Prostate capsule CTV1 Offenbach Prostate capsule CTV1
23 Boost History EBRT in Offenbach ADT Androgen Deprivation Therapy 9 month 3 month neoadjuvant
24 BOOST to EBRT Androgen Deprivation Therapy Huggins
25 BOOST to EBRT LHRH-Agonists -continuously- LH Testosteron flare up Ø pulsatile Anti-androgens
26 BOOST to EBRT Zelefsky 2008: We observed a benefit for ADT in high-risk patients who received higher doses. Int. J. Radiation Oncology Biol. Phys. Vol.71 No , 2008
27 Boost/EBRT History Results Galalae et. al. Vargas et. al. Offenbach Cases OS 85 % 92% 73.3 % CSS 96 % 98 % 91,9 % BC 77 % 78.4 % 76.2 % DFS 67 % 84.8 % 76.8 % OS= overall survival, CSS = cause specific survival, BC = biochemical control (5-year), DFS = disease-free survival Galalae et. al.; Int. J. Radiation Oncology Biol. Phys. 58, Vargas et. al.; Int. J. Radiation Oncology Biol. Phys. 66,
28 Boost/EBRT Toxicity urogenital (%) gastrointestinal (%) CTC akut chronic akut chronic I II III IV (1)
29 HDR-Brachytherapy in Offenbach Monotherapy
30 HDR Monotherapy Clinical stage < T2c and PSA < 10.0 and Gleason 7a (3+4)
31 HDR Monotherapy Since 2001: transperineal HDR 4 x 9,5 Gy 1 implant (4 x 9.5 Gy) 2 implants (2 x 9.5 Gy per implant) 577 Patients HDR 3 x 11,5 Gy 114 Patients
32 HDR Monotherapy Protocols: Martinez 1 implant 2 days 4x9.5 Gy 38 Gy Rodriguez 2 implants 1 day 6x7 Gy 42 Gy Gustafson 1 implant 2 days 4x9.5 Gy 38 Gy 2 implants 1 day 6x7 Gy 42 Gy Offenbach 3 Implants 1 day 3x11.5 Gy 34.5 Gy Int J Radiat Oncol Biol Phys 2000; 47: International Brachytherapy Meeting, Santa Fe, 2002 Int J Radiat Oncol Biol Phys 2003; 57, Suppl, Abstract 176, p
33 Athens - Conference HDR MONOTHERAPY OPTIONS Dose Gy # Fxs Total D Gy BED α/β 1.5 % Dose D 2Gy
34 HDR Monotherapy Toxicity akut urogenital (%) G0 GI GII GIII GIV 1 Implant 2 Implants
35 HDR Monotherapy 3 patients with rectal ulceration 1 patient with rectal and urethral fistula, definitive Colo- and Urostomie 1 patient with urethro-prostatic fistula Severe chronic toxicity only in patients with CT Planning and 4 fractions with 1 implant
36 HDR-Brachytherapy in Offenbach Results / Studies
37 HDR-Brachytherapy Summary Since 1996: 2527 Patients Transrectal HDR 4 X 5-7 Gy + EBRT 39,6 45 Gy 1450 Patients Tarnsperineal HDR 4 x 9,5 Gy HDR 3 x 11,5 Gy 577 Patients 114 Patients HDR 3 x 7,0 Gy + EBRT 45 Gy 258 Patients HDR 2 x 10,5 Gy + EBRT 45 Gy 88 Patients Salvage: HDR 4 x 6,0 Gy 40 Patients
38 PSA-level Distribution 70,0 60,0 50,0 % 40,0 30,0 20,0 10,0 0,0 PSA < 5 PSA 5-10 PSA PSA > 20 PSA >100 3% of Patients with PSA <4 ng/ml at the time of Diagnosis!!!
39 Clinical Stage Distribution 40 % T1c T2a T2b T2c T3a low intermediate high
40 Questionaire History Since Questions: - QLQ 30 - IPSS - IIEF
41 Sexual History Activity - without ADT 52,8 % sexual Activivty 47,2 % no sexual Activivty Nearly 50% have no sexual activity (median age: 71 years)
42 Sexual History Activity - with ADT 20 % sexual Activivty
43 IPSS History 72 patients - QLQ 30 - IPSS - IIEF - Incomplete emptying - Frequency - Intermittency - Urgency - Weak stream - Straining - Nocturia 0-5 points / question
44 IPSS IPSS - total score 0 35 points score symptomatic 0 7 mildly symptomatic 8 19 moderatly symptomatic severely symptomatic
45 IPSS History pretreatment - IPSS Posttreatment - IPSS 24 patients (mildly) 37 patients (mildly) 10 patients (moderatly) 03 patients (severely) 01 patients (mildly) 32 patients (moderatly) 23 patients (moderatly) 08 patients (severely) 00 patients (mildly) 03 patients (severely) 01 patients (moderatly) 02 patients (severely)
46 IPSS History - Seed Wylie et. al median
47 IPSS History - Seed?
48 HDR-Brachytherapy of Prostate Cancer - Logistics -
49
50 Saddle block or spinal anaesthesia
51 Lithotomy position
52 Preparing the system
53 Fixation of the probe and template on the stepper
54 Fixation needles
55 Treatment catheters
56 Theater I 1. Patient 3. Patient Spinal-Anaesthesia A Imobilization N Acquisition: U+P Contouring: R Implantation: U+P Acquisition: U+P Contouring: R Final Plan: P+(R) Treatment delivery Spinal-Anaesthesia A Imobilization N Acquisition: U + P Contouring: R Implantation: U+P Theater II 2. Patient 4. Patient Spinal-Anaesthesia A Imobilization N Acquisition: U + P Contouring: R Implantation: U+P Acquisition: U+P Contouring: R Final Plan: P+(R) Treatment delivery Spinal-Anaesthesia A
57 THANK YOU FOR YOUR ATTENTION.
The benefit of a preplanning procedure - view from oncologist. Dorota Kazberuk November, 2014 Otwock
The benefit of a preplanning procedure - view from oncologist Dorota Kazberuk 21-22 November, 2014 Otwock Brachytherapy is supreme tool in prostate cancer management with a wide range of options in every
PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College
PROSTATE CANCER BRACHYTHERAPY Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College Risk categorization Very Low Risk Low Risk Intermediate Risk High Risk
HDR vs. LDR Is One Better Than The Other?
HDR vs. LDR Is One Better Than The Other? Daniel Fernandez, MD, PhD 11/3/2017 New Frontiers in Urologic Oncology Learning Objectives Indications for prostate brachytherapy Identify pros/cons of HDR vs
LDR Monotherapy vs. HDR Monotherapy
Abstract No. 1234 LDR Monotherapy vs. HDR Monotherapy Is it time for LDR to retire? Gerard Morton 2 LDR Seed Brachytherapy First 2000 LDR patients from BCCA Low and Intermediate Risk LDR Implant Morris
BRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital
BRACHYTHERAPY FOR PROSTATE CANCER Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital PROSTATE BRACHYTHERAPY Why brachytherapy? How do we do it? What are the results? Questions?
Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date
MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
Section: Therapy Effective Date: October 15, 2016 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2016 Page: 1 of 10 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
New research in prostate brachytherapy
New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic
Index. B Biologically effective dose (BED), 158
Index B Biologically effective dose (BED), 158 C Catheter displacement, 113, 114 rectal probe, 114 self-anchoring catheters, 113 Catheter fixation, HDR, 106 107 Catheter insertion, HDR sagittal ultrasound
TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY
TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 1 TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY BRENDAN CAREY, MD TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 2 TRANSRECTAL ULTRASOUND-GUIDED
18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April
Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and
2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
How can we best use HDR brachytherapy to escalate dose in intermediate and high risk disease? Gerard Morton Associate Professor
How can we best use HDR brachytherapy to escalate dose in intermediate and high risk disease? Gerard Morton Associate Professor Objectives Why should we escalate dose? What HDR dose and fractionation should
Description. Section: Therapy Effective Date: October 15, 2015 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2015 Page: 1 of 14 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT
Donald B. Fuller, M.D. 1, John Naitoh, M.D. 2, Mark Reilly, M.D. 3, Chad Lee, Ph.D 1. 1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT Typically,
Brachytherapy for Prostate Cancer
Brachytherapy for Prostate Cancer Who should be thinking about this and why... Juanita Crook Professor Radiation Oncology University of Toronto Princess Margaret Hospital Many options watchful waiting?
HDR Brachytherapy: Results and Future Studies in Monotherapy
HDR Brachytherapy: Results and Future Studies in Monotherapy Nikolaos Zamboglou and Nikolaos Tselis Strahlenklinik Klinikum Offenbach - Germany Prostate Brachytherapy UK & Ireland Conference 2013 Comparison
Prostate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
PSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
Definition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
Clinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
Embracing Technology & Timing of Salvage Hormones
Embracing Technology & Timing of Salvage Hormones Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology Sunnybrook Health Sciences Centre University of Toronto Us Too, Brampton October
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre
The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation Roberto Alonzi Mount Vernon Cancer Centre Overview Introduction and rationale for focused dose escalation
Medical Policy. MP High-Dose Rate Temporary Prostate Brachytherapy
Medical Policy MP 8.01.33 BCBSA Ref. Policy: 8.01.33 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.79 Cryoablation of Prostate Cancer 8.01.10 Charged-Particle
or low dose rate (LDR), brachytherapy
High dose rate brachytherapy for prostate cancer: Current techniques and applications to varying disease presentations Daniel J. Krauss, MD High dose rate (HDR) brachytherapy has been an option for managing
Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy
Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy Policy #: 024 Latest Review Date: June 2014 Category: Therapy Policy Grade: C Background/Definitions: As a general rule, benefits are payable
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure
Brachytherapy in prostate cancer: techniques and clinical outcomes
19 Brachytherapy in prostate cancer: techniques and clinical outcomes MARK PRENTICE, WENLONG NEI, AMY LEWIS, REENA DAVDA AND HEATHER PAYNE Brachytherapy for prostate cancer involves placing radioactive
SRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
DOSE ESCALATION USING CONFORMAL HIGH-DOSE-RATE BRACHYTHERAPY IMPROVES OUTCOME IN UNFAVORABLE PROSTATE CANCER
PII S0360-3016(02)02733-5 Int. J. Radiation Oncology Biol. Phys., Vol. 53, No. 2, pp. 316 327, 2002 Copyright 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/02/$ see front
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients Tselis et al. Tselis et al. Radiation Oncology 213, 8:115
Vital role of volume and number of needles in HDR brachytherapy (HDR-BT) of prostate cancer
Original article Clinical Investigations Vital role of volume and number of needles in HDR brachytherapy (HDR-BT) of prostate cancer Adam Chichel/, MD, Marek Kanikowski, MD, Janusz Skowronek, MD, PhD,
CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
The Spa Hotel, Tunbridge Wells Friday 23 rd March Platinum sponsor
The Spa Hotel, Tunbridge Wells Friday 23 rd March 2018 Platinum sponsor ADT in brachytherapy Adding efficacy or just toxicity C. Salembier Department of Radiotherapy-Oncology Europe Hospitals Brussels
doi: /s (03) CLINICAL INVESTIGATION
doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
In autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
Predicting (and avoiding) Morbidity in LDR Prostate Brachytherapy
Predicting (and avoiding) Morbidity in LDR Prostate Brachytherapy Juanita Crook Professor Radiation Oncology University of Toronto University of British Columbia BCCA CSI 1 Categories of Morbidity Urinary
PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
Brachytherapy Planning and Quality Assurance w Classical implant systems and modern computerized dosimetry w Most common clinical applications w
Brachytherapy Planning and Quality Assurance w Classical implant systems and modern computerized dosimetry w Most common clinical applications w Quality assurance Classical implant systems w Manchester
Brachytherapy Planning and Quality Assurance
Brachytherapy Planning and Quality Assurance Classical implant systems Most common clinical applications and modern dosimetry methods Quality assurance Classical implant systems Manchester (Paterson-Parker)
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
Open clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
AllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
Central European Journal of Urology
270 Central European Journal of Urology O R I G I N A L P A P E R urological oncology Low-dose-rate brachytherapy as a minimally invasive curative treatment for localised prostate cancer has excellent
Johannes C. Athanasios Dimopoulos
BrachyNext Symposium Miami Beach, USA, May 30 31, 2014 Imaging Modalities: Current Challenges and Future Directions Johannes C. Athanasios Dimopoulos Imaging Modalities: Current Challenges and Future Directions
Debate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
Patterns of care for prostate cancer An update
Patterns of care for prostate cancer An update Daniel Moon Director of Robotic Surgery Epworth Healthcare Honorary Clinical Senior Lecturer University of Melbourne Consultant Urologist Peter MacCallum
External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
External Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical
Prostate Cancer. GU Practice Guideline
Prostate Cancer GU Practice Guideline This guideline is a statement of consensus of the GU Disease Site Team regarding their views of currently accepted approaches to treatment. It is not intended to replace
ARTICLE. The current role of imaging for prostate brachytherapy
Cancer Imaging (2007) 7, 27 33 DOI: 10.1102/1470-7330.2007.0003 ARTICLE The current role of imaging for prostate brachytherapy Brendan Carey and Sarah Swift Radiology Department, Cookridge Hospital, Leeds,
Salvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy
Case report Salvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy Lynn Chang, MD 1, Mark K. Buyyounouski, MD, MS 2 Case Report 1 Department of Radiation
RALP Registration Form (new registration)
RALP Registration Form (new registration) RALP registration form new registration v2.0 1 RALP registration form new registration All fields are required, except those marked with an asterisk (*) Variables
The Evolution of RT Techniques for Gynaecological Cancers in a developing country context
The Evolution of RT Techniques for Gynaecological Cancers in a developing country context Hannah Simonds Stellenbosch University/ Tygerberg Academic Hospital ESMO Africa 2017 I have no disclosures External
Overview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
FOCAL THERAPY PROSTATE SEED BRACHYTHERAPY
FOCAL THERAPY PROSTATE SEED BRACHYTHERAPY DR. JOSEPH BUCCI MBBS,FRACP,FRANZCR ST. GEORGE CANCER CARE CENTRE PATIENT 47 2005 66 year old Recently remarried - old childhood sweetheart PSA 6.2, ct1c, Gleason
Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer?
Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer? Dimos Baltas 1,3, Natasa Milickovic 1, Nikolaos Zamboglou 2 1 Dept. of Medical Physics & Engineering, 2 Strahlenklinik,
Prostate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
Review paper Educational Activity High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective Yasuo Yoshioka, MD, PhD 1, Osamu Suzuki, MD, PhD 1, Yuki Otani, PhD
Prostate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends
Prostate Cancer: Low Dose Rate (Seed) Brachytherapy Information for patients, families and friends About this booklet This booklet is designed to give you information about low dose-rate (seed) brachytherapy
Radiotherapy and Oncology
Radiotherapy and Oncology 107 (2013) 325 332 Contents lists available at SciVerse ScienceDirect Radiotherapy and Oncology journal homepage: www.thegreenjournal.com GEC/ESTRO recommendations GEC/ESTRO recommendations
Original articles. Abstract. Purpose
Original article Original articles Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost Adam
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
High Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
How to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
Abstract Purpose: Material and methods: Results: Conclusions: Key words: Purpose Address for correspondence:
Original paper Physics Contributions The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy
Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery
Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico
Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
DOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS
DOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS Andrius IVANAUSKAS*, Eduardas ALEKNAVIČIUS*, Arvydas BURNECKIS*, Albert MILLER *Institute of Oncology Vilnius
Screening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
New Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant
Radiotherapy, Article ID 130652, 6 pages http://dx.doi.org/10.1155/2014/130652 Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103
The Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced
Clinical Urology High-Dose Rate Brachytherapy for Prostate Cancer International Braz J Urol Vol. 34 (3): 293-301, May - June, 2008 Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy
The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
Prostate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes
ORIGINAL ARTICLE Vol. 41 (3): 435-441, May - June, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0289 Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy
Hormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
Radiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
pat hways Medtech innovation briefing Published: 16 December 2014 nice.org.uk/guidance/mib16
pat hways The Oncentra Prostate v4.x for ultrasound-guided real-time HDR brachytherapy in men with localised prostate cancer Medtech innovation briefing Published: 16 December 2014 nice.org.uk/guidance/mib16